Serum lipid levels during interferon therapy in patients with chronic hepatitis C.
Interferon-alpha (IFN-alpha) may affect lipid metabolism by stimulating hepatic fatty acid synthesis. The aim of this study was to evaluate serum lipid levels during IFN-alpha therapy in patients with biopsy-proven chronic active hepatitis C. A total of 22 patients (18 males and 4 females; age 25-55 years) received 3 MU of recombinant IFN-alpha 2b 3 times a week for 6 months. Serum lipids were determined at baseline and then every month until the end of therapy. All patients had normal serum lipid levels at baseline. No significant level of modification occurred in patients during the therapy. An increase in serum lipid levels during low-dose IFN-alpha therapy seems to be uncommon in hepatitis C virus-infected patients with baseline normal levels.
Picciotto
A
A
Department of Internal Medicine, University of Genoa, Italy.
Bertolini
S
S
Bardellini
E
E
Borro
P
P
Borzone
S
S
Masturzo
P
P
Pireddu
M
M
Sinelli
N
N
Celle
G
G
D000328:Adult; D001706:Biopsy; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006521:Hepatitis, Chronic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008055:Lipids; D011994:Recombinant Proteins